IVVD

Invivyd, Inc. Common Stock (IVVD) | Rumor.io

Invivyd

IVVD

Attention (50-day avg)0%

Attention rank (50-day avg)#942

Bullish sentiment (50-day avg)88%

Price to earnings ratio-3.18

Market capitalization280M

Earnings per share-0.31

Dividend yield (TTM)—

Revenue (annual)53.4M

Net income (annual)-52.5M

Social

What share of all stock conversation is about IVVD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.01	0% +0	0% 0	0% -0.01

Sep 29

Invivyd, Inc. ($IVVD) announced positive topline results from its Phase 3 LIBERTY study, demonstrating VYD2311's safety and tolerability superiority over mRNA-based COVID-19 vaccines.
The company plans to submit a BLA (Biologics License Application) for VYD2311, and accelerated approval could be a game-changer.
The Phase 3 study showed that VYD2311 met primary and key secondary safety endpoints while enhancing antibody titers when combined with an mRNA vaccine.

Generated by AI

Sentiment

Of the messages about IVVD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	65.91% -19.28	75.56% -8.27	76.71% -19.85	85.83% +22.58
Bearish	34.09% +19.28	24.44% +8.27	23.29% +19.85	14.17% -22.58

Bullish· Sep 21

Invivyd, Inc. ($IVVD) has seen a significant increase in price, up 32% today, potentially indicating a positive update on its COVID antibody.
The company's Phase 3 trial results are expected to be released soon, which could lead to a further increase in price, potentially reaching $1.50 or higher by the end of the year.
Invivyd's stock has seen a notable surge in trading volume, with a 20.3% increase today, and no filing in the window explaining the sudden surge, which could be a sign of positive news or a bullish market sentiment.

Bearish· Nov 17

$IVVD's recent offerings of 74.8M shares at $0.52 and another offering at an unknown price are expected to dilute shareholders and lead to a further price drop.
The company's proposed public offering and ATM program may result in a 350M dilution, causing the stock to fall below its $2.24 low.
The stock's recent price movement is attributed to a fake dead cat bounce, with the author expecting a significant price drop once trading volume increases.

Generated by AI

Topics

Of the messages about IVVD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	77.78%	87.9%	34.2%
Technical Analysis	0%	22.22%	6.45%	14.86%
Analysts	0%	0%	5.65%	24.6%
Macro	0%	0%	0%	20.78%
Controversies	0%	0%	0%	1.74%
Earnings	0%	0%	0%	3.82%

Announcements· Apr 9

Invivyd, Inc. ($IVVD) announced progress on its REVOLUTION Program, highlighting its monoclonal antibody candidate VMS063 for measles treatment and prevention.
The company revealed plans to test an antibody drug against measles, with potential for a first-in-class treatment and prevention option.
Shares of Invivyd jumped following the announcement, with the stock price increasing by around 22% on the news.

Technical Analysis· Aug 26

$IVVD has broken through resistance with high volume and overbought RSI, suggesting a strong bullish momentum.
The stock has formed a series of ABCD waves, with a pullback and consolidation near VWAP at $1.07, and is now building higher lows.
$IVVD has a strong trendline support from $1.10, and is currently pushing above $1.20, with a strong momentum above VWAP at $1.03.

Generated by AI

Community

Of the messages about IVVD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	35.58%	38.68%	53.17%	40.59%
Newcomers	64.42%	61.32%	46.83%	59.41%

Regulars· Sep 29

The LIBERTY Phase 3 study topline results demonstrated VYD2311 safety and tolerability superiority to an mRNA-based COVID-19 vaccine.
The company plans to submit a Biologics License Application (BLA) for VYD2311, and the safety data from the trial showed VYD2311 to be better tolerated than Comirnaty.
The market's reaction to the safety data release, but not the efficacy data, is seen as a negative sign by some, while others believe the trend is strengthening with time.

Newcomers· Sep 29

The Phase 3 LIBERTY study of Invivyd's COVID-19 monoclonal antibody candidate demonstrated that VYD2311 met primary and key secondary safety endpoints while enhancing antibody titers when combined with an mRNA vaccine.
The company's long-term lease agreement is seen as a confirmation of the data they have, which is a catalyst for the stock's jump, and the accelerated approval strategy appears to have been developed through active FDA engagement.
The upcoming October DECLARATION update will be critical in determining the stock's direction, particularly given the regulatory path chosen, and additional participants will be enrolled in a confirmatory randomized cohort to ensure the clinical efficacy readout is sufficiently powered.

Generated by AI

News

Why Is Invivyd Stock Trading Lower Today? - Invivyd (NASDAQ:IVVD)

Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.

17h agoBenzinga

Invivyd delays trial data for COVID drug (IVVD:NASDAQ)

Invivyd (IVVD) stock falls as the company delays a key readout from a late-stage trial for its COVID-19 therapy. VYD2311. Read more here.

19h agoSeeking Alpha

Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission

Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA pending supportive results from its ongoing DECLARATION study. Key Investor TakeawaysInvivyd (NASDAQ:IVVD) said VYD2311 showed significantly lower rates of short-term overall adverse events and systemic adverse events than the mRNA COVID-19 vaccine in the Phase 3 LIBERTY study.

21h agoYahoo Finance

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - Slideshow (NASDAQ:IVVD) 2026-09-29

22h agoSeeking Alpha

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccineVYD2311 combined with an mRNA-based COVID-19 vaccine demonstrated no interference with vaccine-induced neutralizing titers, and instead added substantially to vaccine-induced neutralizing titersVYD2311 observed profile in LIBERTY indicates hig

1d agoYahoo Finance

Invivyd at H.C. Wainwright conference: push for broader antibody market

15d agoInvesting.com

Also Discussed

Investors talking about IVVD also mention

#	Name	Attention
1	Society Pass IncorporatedSOPA	0%0
2	ALLK - Allakos Inc.	——
3	Biofrontera Inc.BFRI	0%0
4	HCW Biologics Inc.HCWB	0%0
5	Lendway Inc.LDWY	0%new
6	Longeveron Inc. Class A Common StockLGVN	0%0
7	SGMA - SigmaTron International, Inc.	——
8	Pasithea Therapeutics Corp.KTTA	0%0
9	Nutriband Inc.NTRB	0%0
10	CALT - Calliditas Therapeutics AB (publ)	——

Invivyd, Inc. Common Stock

Healthcare
Biotechnology

Invivyd, Inc. Common Stock is the equity of Invivyd, a biopharmaceutical company focused on developing and commercializing monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. The company’s current work centers on antibody-based solutions for COVID-19 and other respiratory viruses, supported by a proprietary platform that combines viral surveillance, predictive modeling, and antibody engineering. Its marketed and clinical-stage programs include PEMGARDA (pemivibart) and additional antibody candidates being developed for viral threats such as COVID-19, RSV, and measles. Invivyd serves the healthcare and biotechnology markets by advancing specialized biologic products designed for patients with limited preventive or treatment options, particularly immunocompromised populations. The company is headquartered in New Haven, Connecticut.

Website

Location

209 Church Street

New Haven, CT, 06510

United States

Social

What share of all stock conversation is about IVVD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.01	0% +0	0% 0	0% -0.01

Sep 29

Invivyd, Inc. ($IVVD) announced positive topline results from its Phase 3 LIBERTY study, demonstrating VYD2311's safety and tolerability superiority over mRNA-based COVID-19 vaccines.
The company plans to submit a BLA (Biologics License Application) for VYD2311, and accelerated approval could be a game-changer.
The Phase 3 study showed that VYD2311 met primary and key secondary safety endpoints while enhancing antibody titers when combined with an mRNA vaccine.

Generated by AI

Sentiment

Of the messages about IVVD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	65.91% -19.28	75.56% -8.27	76.71% -19.85	85.83% +22.58
Bearish	34.09% +19.28	24.44% +8.27	23.29% +19.85	14.17% -22.58

Bullish· Sep 21

Invivyd, Inc. ($IVVD) has seen a significant increase in price, up 32% today, potentially indicating a positive update on its COVID antibody.
The company's Phase 3 trial results are expected to be released soon, which could lead to a further increase in price, potentially reaching $1.50 or higher by the end of the year.
Invivyd's stock has seen a notable surge in trading volume, with a 20.3% increase today, and no filing in the window explaining the sudden surge, which could be a sign of positive news or a bullish market sentiment.

Bearish· Nov 17

$IVVD's recent offerings of 74.8M shares at $0.52 and another offering at an unknown price are expected to dilute shareholders and lead to a further price drop.
The company's proposed public offering and ATM program may result in a 350M dilution, causing the stock to fall below its $2.24 low.
The stock's recent price movement is attributed to a fake dead cat bounce, with the author expecting a significant price drop once trading volume increases.

Generated by AI

Topics

Of the messages about IVVD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	77.78%	87.9%	34.2%
Technical Analysis	0%	22.22%	6.45%	14.86%
Analysts	0%	0%	5.65%	24.6%
Macro	0%	0%	0%	20.78%
Controversies	0%	0%	0%	1.74%
Earnings	0%	0%	0%	3.82%

Announcements· Apr 9

Invivyd, Inc. ($IVVD) announced progress on its REVOLUTION Program, highlighting its monoclonal antibody candidate VMS063 for measles treatment and prevention.
The company revealed plans to test an antibody drug against measles, with potential for a first-in-class treatment and prevention option.
Shares of Invivyd jumped following the announcement, with the stock price increasing by around 22% on the news.

Technical Analysis· Aug 26

$IVVD has broken through resistance with high volume and overbought RSI, suggesting a strong bullish momentum.
The stock has formed a series of ABCD waves, with a pullback and consolidation near VWAP at $1.07, and is now building higher lows.
$IVVD has a strong trendline support from $1.10, and is currently pushing above $1.20, with a strong momentum above VWAP at $1.03.

Generated by AI

Community

Of the messages about IVVD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	35.58%	38.68%	53.17%	40.59%
Newcomers	64.42%	61.32%	46.83%	59.41%

Regulars· Sep 29

The LIBERTY Phase 3 study topline results demonstrated VYD2311 safety and tolerability superiority to an mRNA-based COVID-19 vaccine.
The company plans to submit a Biologics License Application (BLA) for VYD2311, and the safety data from the trial showed VYD2311 to be better tolerated than Comirnaty.
The market's reaction to the safety data release, but not the efficacy data, is seen as a negative sign by some, while others believe the trend is strengthening with time.

Newcomers· Sep 29

The Phase 3 LIBERTY study of Invivyd's COVID-19 monoclonal antibody candidate demonstrated that VYD2311 met primary and key secondary safety endpoints while enhancing antibody titers when combined with an mRNA vaccine.
The company's long-term lease agreement is seen as a confirmation of the data they have, which is a catalyst for the stock's jump, and the accelerated approval strategy appears to have been developed through active FDA engagement.
The upcoming October DECLARATION update will be critical in determining the stock's direction, particularly given the regulatory path chosen, and additional participants will be enrolled in a confirmatory randomized cohort to ensure the clinical efficacy readout is sufficiently powered.

Generated by AI

Invivyd

Social

Sep 29

Bullish· Sep 21

Bearish· Nov 17

Announcements· Apr 9

Technical Analysis· Aug 26

Regulars· Sep 29

Newcomers· Sep 29

Why Is Invivyd Stock Trading Lower Today? - Invivyd (NASDAQ:IVVD)

Invivyd delays trial data for COVID drug (IVVD:NASDAQ)

Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - Slideshow (NASDAQ:IVVD) 2026-09-29

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

Invivyd at H.C. Wainwright conference: push for broader antibody market

Also Discussed

Invivyd, Inc. Common Stock

Company Information

Location

Why Is Invivyd Stock Trading Lower Today? - Invivyd (NASDAQ:IVVD)

Invivyd delays trial data for COVID drug (IVVD:NASDAQ)

Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - Slideshow (NASDAQ:IVVD) 2026-09-29

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

Invivyd at H.C. Wainwright conference: push for broader antibody market

Also Discussed

Social

Sep 29

Bullish· Sep 21

Bearish· Nov 17

Announcements· Apr 9

Technical Analysis· Aug 26

Regulars· Sep 29

Newcomers· Sep 29